Ancilia Bio Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$10.1M
- Investors
-
15
Ancilia Bio General Information
Description
Developer of virus-resistant live bacterial products designed to modulate the human microbiome. The company targets the viral components of the gut microbiome to treat disease and focuses on healthy gut bacteria and their predatory phages to engineer resistant strains, and also develops a new class of live biotherapeutics, enabling medical science professionals to specifically target phages or viruses with a specific affinity for inducing lysis.
Contact Information
Website
www.anciliabio.comCorporate Office
- 45-18 Court Square West
- Long Island City
- New York, NY 11101
- United States
Corporate Office
- 45-18 Court Square West
- Long Island City
- New York, NY 11101
- United States
Ancilia Bio Timeline
Ancilia Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Seed Round | 06-Apr-2026 | $10.1M | Completed | Generating Revenue | ||
| 5. Grant | 23-Oct-2024 | Completed | Generating Revenue | |||
| 4. Grant | 23-Oct-2024 | Completed | Generating Revenue | |||
| 3. Debt - General | 04-May-2023 | Completed | Generating Revenue | |||
| 2. Grant | 03-Aug-2021 | $256K | $63.4K | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | 01-Jan-2019 | $63.4K | $63.4K | Completed | Generating Revenue |
Ancilia Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
Ancilia Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ancilia Bio Patents
Ancilia Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026122938-A1 | Compositions and methods for protecting and restoring vaginal microbiota | Pending | 06-Dec-2024 |
Ancilia Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ancilia Bio Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bioverge | Venture Capital | Minority | ||
| Defined | Venture Capital | Minority | ||
| Harmonix Fund | Venture Capital | Minority | ||
| MBX Capital | Venture Capital | Minority | ||
| Metaplanet | Corporation | Minority |
Ancilia Bio FAQs
-
When was Ancilia Bio founded?
Ancilia Bio was founded in 2019.
-
Where is Ancilia Bio headquartered?
Ancilia Bio is headquartered in New York, NY.
-
What is the size of Ancilia Bio?
Ancilia Bio has 5 total employees.
-
What industry is Ancilia Bio in?
Ancilia Bio’s primary industry is Drug Discovery.
-
Is Ancilia Bio a private or public company?
Ancilia Bio is a Private company.
-
What is the current valuation of Ancilia Bio?
The current valuation of Ancilia Bio is .
-
What is Ancilia Bio’s current revenue?
The current revenue for Ancilia Bio is .
-
How much funding has Ancilia Bio raised over time?
Ancilia Bio has raised $11.1M.
-
Who are Ancilia Bio’s investors?
Bioverge, Defined, Harmonix Fund, MBX Capital, and Metaplanet are 5 of 15 investors who have invested in Ancilia Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
